



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Spastin (m): 293T Lysate: sc-123732

BACKGROUND

The AAA protein family members share an ATPase domain and have roles in various cellular processes, including intracellular motility, membrane trafficking, proteolysis, protein folding and organelle biogenesis. Spastin, a member of the AAA protein family, is a 616 amino acid protein and is involved in the function or assembly of nuclear protein complexes. The Spastin protein is expressed ubiquitously and localizes to the nucleus and the cytoplasm, where it may also be involved in microtubule dynamics. Mutations in the Spastin gene (SPAST, SPG4) cause the most common form of spastic paraplegia 4, an autosomal dominant form of hereditary spastic paraplegia (HSP). HSPs comprise a group of inherited neurological disorders characterized by spastic lower extremity weakness due to a length-dependent, retrograde axonopathy of corticospinal motor neurons. SPAST-specific mutations account for approximately 40% of all autosomal dominant HSPs.

REFERENCES

- Nielsen, J.E., Johnsen, B., Koefoed, P., Scheuer, K.H., Grønbech-Jensen, M., Law, I., Krabbe, K., Nørremølle, A., Eiberg, H., Søndergård, H., Dam, M., Rehfeld, J.F., Krarup, C., Paulson, O.B., Hasholt, L. and Sørensen, S.A. 2004. Hereditary spastic paraplegia with cerebellar ataxia: a complex phenotype associated with a new SPG4 gene mutation. *Eur. J. Neurol.* 11: 8178-8124.
- Scheuer, K.H., Nielsen, J.E., Krabbe, K., Simonsen, C., Koefoed, P., Sørensen, S.A., Gade, A., Paulson, O.B. and Law, I. 2005. Reduced regional cerebral blood flow in SPG4-linked hereditary spastic paraplegia. *J. Neurol. Sci.* 235: 23-32.
- Alber, B., Pernauer, M., Schwan, A., Rothmund, G., Hoffmann, K.T., Brummer, D., Sperfeld, A.D., Uttner, I., Binder, H., Epplen, J.T., Dullinger, J., Ludolph, A.C. and Meyer, T. 2005. Spastin related hereditary spastic paraplegia with dysplastic corpus callosum. *J. Neurol. Sci.* 236: 9-12.
- Claudiani, P., Riano, E., Errico, A., Andolfi, G. and Rugarli, E.I. 2005. Spastin subcellular localization is regulated through usage of different translation start sites and active export from the nucleus. *Exp. Cell Res.* 309: 358-369.
- Meyer, T., Schwan, A., Dullinger, J.S., Brocke, J., Hoffmann, K.T., Nolte, C.H., Hopt, A., Kopp, U., Andersen, P., Epplen, J.T. and Linke, P. 2005. Early-onset ALS with long-term survival associated with Spastin gene mutation. *Neurology* 65: 141-143.
- Svenson, I.K., Kloos, M.T., Jacon, A., Gallione, C., Horton, A.C., Pericak-Vance, M.A., Ehlers, M.D. and Marchuk, D.A. 2005. Subcellular localization of Spastin: implications for the pathogenesis of hereditary spastic paraplegia. *Neurogenetics* 6: 135-141.
- Winner, B., Gross, C., Uyanik, G., Schulte-Mattler, W., Lürding, R., Marienhagen, J., Bogdahn, U., Windpassinger, C., Hehr, U. and Winkler, J. 2006. Thin corpus callosum and amyotrophy in spastic paraplegia—Case report and review of literature. *Clin. Neurol. Neurosurg.* 108: 692-698.
- Depienne, C., Tallaksen, C., Lephay, J.Y., Bricka, B., Poëa-Guyon, S., Fontaine, B., Labauge, P., Brice, A. and Durr, A. 2006. Spastin mutations are frequent in sporadic spastic paraparesis and their spectrum is different from the one observed in familial cases. *J. Med. Genet.* 43: 259-265.

CHROMOSOMAL LOCATION

Genetic locus: Spg4 (mouse) mapping to 17 E2.

PRODUCT

Spastin (m): 293T Lysate represents a lysate of mouse Spastin transfected 293T cells and is provided as 100 µg protein in 200 µl SDS-PAGE buffer.

APPLICATIONS

Spastin (m): 293T Lysate is suitable as a Western Blotting positive control for mouse reactive Spastin antibodies. Recommended use: 10-20 µl per lane.


Control 293T Lysate: sc-117752 is available as a Western Blotting negative control lysate derived from non-transfected 293T cells.

Spastin (Sp 3G11/1): sc-53443 is recommended as a positive control antibody for Western Blot analysis of enhanced mouse Spastin expression in Spastin transfected 293T cells (starting dilution 1:100, dilution range 1:100-1:1,000).

RECOMMENDED SUPPORT REAGENTS

To ensure optimal results, the following support reagents are recommended:
 1) Western Blotting: use m-IgGκ BP-HRP: sc-516102 or m-IgGκ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker™ Molecular Weight Standards: sc-2035, UltraCruz® Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048.

DATA



Spastin (Sp 3G11/1): sc-53443. Western blot analysis of Spastin expression in non-transfected: sc-117752 (A) and mouse Spastin transfected: sc-123732 (B) 293T whole cell lysates.

STORAGE

Store at -20° C. Repeated freezing and thawing should be minimized. Sample vial should be boiled once prior to use. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.